NCT01715636

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Andrew Carr · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study aims to describe the safety, tolerability and adherence to the coformulated anti-HIV drug tenofovir-emtricitabine-rilpivirine (eviplera) when given to men who have sex with men (MSM) following an actual or potential sexual exposure to HIV. This biomedical intervention is known as nonoccupational post-exposure prophylaxis (NPEP). Patients receive NPEP if they meet the criteria outlined in the 2007 National Australian NPEP Guidelines. Three or two anti-HIV drugs are administered for 28-days depending on the severity of the the assessed HIV acquisition risk. In this study eviplera would constitute 3-drug NPEP. Tenofovir-emtricitabine (truvada) a component of eviplera has been used in NPEP at SVH since 2006. This is a multi site, prospective, open-label, non-randomised trial. Participants will be MSM who present at the various recruitment sites requesting NPEP. Initially, 50 eligible participants will be assigned to receive eviplera 25mg once daily taken with food for 28-days according to established Australian guidelines for the use of 3-drug NPEP. There will be 7 visits over a 12-week period. Follow-up post NPEP is for 8 weeks. If an interim analysis demonstrates acceptable safety, it is proposed to seek ethics approval to increase the samples size to 100 patients to gain more accurate information on regimen completion rate and on-drug adherence. The primary study objectives are: 1. To describe the safety of 28 days of NPEP using co-formulated FTC-RPV-TDF 2. To describe the tolerability of 28 days of NPEP using FTC-RPV-TDF 3. To describe on-drug adherence and regimen completion rates of 28 days of NPEP using FTC-RPV-TDF

Conditions

• HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men

Interventions

Type	Name	Description
DRUG	Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg

Timeline

• Start date: 2012-12-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2012-10-29
• Last updated: 2015-01-12

Locations

4 sites across 1 country: Australia